Glenmark Pharma has announced that the US Food and Drug Administration (USFDA) has granted it permission to distribute a generic version of Pfizer’s antibiotic Cleocin capsules. Clindamycin Hydrochloride Capsules with potencies of 75 mg, 150 mg, and 300 mg will be distributed in the United States by Glenmark Pharmaceuticals Inc, an Indian subsidiary.
This endorsement for the nonexclusive medication will give a financially savvy option in contrast to patients requiring anti-infection drug as the Cleocin cases are valued at a higher cost than normal. Cleocin Hydrochloride Capsules, 75 mg, 150 mg, and 300 mg, saw sales of approximately USD 33.6 million, according to IQVIA, for the 12-month period beginning in January 2023.
Glenmark Pharmaceuticals is well-known for its unwavering commitment to creating ground-breaking and cost-effective treatments for chronic conditions like diabetes and asthma. Off-brand and brand-name medicines from a variety of medical fields, including cardiology, dermatology, oncology, and respiratory medicine, are included in their selection. In the fiscal year 2021, the company’s US operations contributed approximately 30% of its gross profits, making them an essential part of its overall earnings.
The approval of Glenmark’s Clindamycin Hydrochloride Capsules by the US Food and Drug Administration (FDA) is a significant milestone for the company because it increases its presence in the largest generic drug market in the world. A number of brand-name medication patents are expected to expire in the upcoming years, resulting in a larger market. The significant role that generic drugs are anticipated to play in reducing healthcare costs is emphasized by the anticipated expansion of the market, particularly in the United States.
